Condition
Pancreatic Ductal Carcinoma
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 4 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
4 shownPhase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C MutationNCT05288205 · 2022-04-14
RECRUITINGA Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsNCT05293496 · 2022-04-19
COMPLETEDA Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in ChinaNCT04121286 · 2020-07-14
COMPLETEDA First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid TumorsNCT04045496 · 2019-09-26
COMPLETEDCommon interventions
Leading sponsors
Trial status mix
COMPLETED3
RECRUITING1
Phase mix
PHASE14
PHASE21
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.